Loxo Oncology Initiates Phase 1 Trial Of Loxo 101, A Selective TRK Inhibitor
5/1/2014 2:11:17 PM
STAMFORD, Conn.--(BUSINESS WIRE)--Loxo Oncology, Inc., a biopharmaceutical company focused on targeted cancer therapies for genetically-defined populations, announced today that it has initiated a Phase 1 Study for its lead compound, LOXO-101, a potent and selective inhibitor of the tropomyosin kinase (TRK) family of receptors. The Phase 1 study will evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of LOXO-101 and, in a second stage, will also provide a preliminary assessment of anti-tumor activity in cancer patients preselected to have an alteration in genes affecting the TRKA, TRKB or TRKC proteins.
Help employers find you! Check out all the jobs and post your resume.
comments powered by